SARS-CoV-2 infection increases the gene expression profile for Alzheimer’s disease risk
The coronavirus disease 2019 (COVID-19) pandemic has caused over 600,000,000 infections globally thus far. Up to 30% of individuals with mild to severe disease develop long COVID, exhibiting diverse neurologic symptoms including dementias. However, there is a paucity of knowledge of molecular brain...
Main Authors: | Ryan Green, Karthick Mayilsamy, Andrew R. McGill, Taylor E. Martinez, Bala Chandran, Laura J. Blair, Paula C. Bickford, Shyam S. Mohapatra, Subhra Mohapatra |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-12-01
|
Series: | Molecular Therapy: Methods & Clinical Development |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2329050122001322 |
Similar Items
-
Acetate-encapsulated Linolenic Acid Liposomes Reduce SARS-CoV-2 and RSV Infection
by: Andrew R. McGill, et al.
Published: (2023-06-01) -
Identification of SARS-CoV-2 Spike Palmitoylation Inhibitors That Results in Release of Attenuated Virus with Reduced Infectivity
by: Ahmed A. Ramadan, et al.
Published: (2022-03-01) -
SARS-CoV-2-Induced Gut Microbiome Dysbiosis: Implications for Colorectal Cancer
by: Mark C. Howell, et al.
Published: (2021-05-01) -
SARS–CoV-2 Immuno-Pathogenesis and Potential for Diverse Vaccines and Therapies: Opportunities and Challenges
by: Andrew R. McGill, et al.
Published: (2021-02-01) -
The viral hypothesis in Alzheimer’s disease: SARS-CoV-2 on the cusp
by: Nanyang Liu, et al.
Published: (2023-03-01)